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years (QALY), costs and the incremental cost-effectiveness and cost-utility ratio 
(ICER and ICUR) of PET-CT versus CT based radiotherapy planning. Model outcomes 
were obtained from averaging the outcome for 50 000 simulated patients. To present 
uncertainty, a probabilistic sensitivity analysis was done. In scenario analyses, we 
explored the effect of varying the input parameters for costs and QALYs and the 
effect of changing the assumptions regarding the multi-state model. Results: The 
incremental costs of PET-CT based planning were € 534 (95% CI: € -4670 – € 6080) for 
0,43 incremental LYs (95% CI: 0,31 – 0,52) and 0,33 QALYs gained (95% CI: 0,26 – 0,45). 
The base-case scenario resulted in an ICER of € 1242 per LY gained and an ICUR 
of € 1618 per QALY gained. The probabilistic sensitivity analysis gave a 41% prob-
ability that PET-CT based planning improves health outcomes at reduced costs and 
a 59% probability that PET-CT based planning is more effective at slightly higher 
costs. ConClusions: PET-based radiotherapy planning for non-small cell lung 
cancer is highly cost-effective compared to CT-based planning.
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objeCtives: The cost-effectiveness of genetic testing for Lynch Syndrome for 
patients newly diagnosed with colorectal cancer in the UK has not previously been 
estimated. Therefore, the cost-effectiveness of nine testing strategies were simulta-
neously compared using a detailed and rigorous mathematical model. Methods: 
In the base case analysis, probands were tested only if aged 50 or below. Testing 
strategies included use of family history, tumour-based tests and genetic testing. 
The clinical pathways of thousands of individual patients diagnosed with colorectal 
cancer (CRC) and their relatives were simulated. For each person, the total costs 
and quality-adjusted life years (QALYs) were calculated using methodology recom-
mended by the National Institute of Health and Care Excellence (NICE). Simulated 
clinical events included incidence of CRC and endometrial cancer (EC); surgery for 
CRC and EC, colonoscopies (including bleeding and perforation), mortality from 
CRC, EC, colonoscopy and background causes. A proportion of people diagnosed 
with Lynch Syndrome were assumed to receive prophylactic hysterectomy and 
to undergo biennial colonoscopies (assumed to reduce the incidence and stage 
of colorectal cancer). The costs of treating patients with CRC with surgery, chem-
otherapy, radiotherapy, stoma care and palliative care were captured. Similarly, 
the costs of treating patients with EC with chemotherapy and radiotherapy were 
included. Results: The life expectancies of probands and relatives with Lynch 
Syndrome are estimated to increase by up to 1.6 years, depending on the strategy 
for genetic testing. All testing strategies are predicted to offer good value for money 
versus no testing, with all incremental cost-effectiveness ratios below the UK basic 
cost-effectiveness threshold of £20,000 per QALY. Universal genetic testing is pre-
dicted to offer poor value for money versus targeted genetic testing. ConClusions: 
Results suggest that targeted genetic testing for Lynch Syndrome for patients with 
newly diagnosed CRC in the UK is a good use of limited financial resources.
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objeCtives: The PillCam COLON2 is a colon capsule endoscopy (CCE) that 
makes a minimally-invasive colonoscopy possible and is expected to improve 
detailed examination rate which have been identified as a problem concerning a 
population-based colorectal cancer (CRC) screening system in Japan. The objective 
of this analysis was to evaluate the cost-effectiveness of CCE if newly introduced 
into the current population-based CRC screening system in Japan. Methods: The 
subject of this analysis was a sequential screening system for which CCE has been 
incorporated (immunochemical fecal occult blood test (IFOBT) → detailed exami-
nation by CCE → detailed examination by colonoscopy) and the comparator was 
the conventional sequential screening system (IFOBT → detailed examination by 
colonoscopy). The target population includes asymptomatic adults aged 40 years 
old and a lifelong simulation was conducted using a Markov model which consists 
of 8 states, no polyp, adenomatous polyp (≤ 5mm, 6-9mm and ≥ 10mm), local-
ized CRC, regional CRC, distant CRC and death. The efficacy measures were life 
year and quality-adjusted life year (QALY). The analysis was conducted from the 
perspective of the payer and only direct medical costs were considered. Results: 
The incremental cost effectiveness ratio (ICER) observed when incorporating CCE 
into the conventional screening system was € 59,911 per QALY, € 25,060 per QALY 
and € 14,905 per QALY when assuming a 10%, a 20% and a 30% improvements in 
detailed examination rates (1 Euro= 128 JPY). Therefore, the introduction of CCE 
was determined to be cost-effective if the detailed examination rate increased by 
20% or more relative to current rate with CCE introduction. ConClusions: Based 
on this analysis, the introduction of CCE into the conventional population-based 
screening system in Japan is shown to be cost-effective. The cost-effectiveness of 
CCE is primarily dependent on the degree of improvement in the current detailed 
examination rate.
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aprepitant price. ConClusions: The using aprepitant plus standard antiemetic 
therapy was more effective and economically justified treatment option for preven-
tion of nausea and vomiting associated with highly and moderately emetogenic 
cancer chemotherapy.
PCN123
ECoNomiC EvaLUatioN of fULvEstraNt 500 mg vErsUs gENEriC NoN-
stEroidaL aromatasE iNhibitors iN PatiENts with advaNCEd brEast 
CaNCEr iN Norway
Ekman M.1, Jacob J.1, Bjørheim J.2
1AstraZeneca Nordic-Baltic, Södertälje, Sweden, 2AstraZeneca Nordic-Baltic, Oslo, Norway
objeCtives: In Norway, breast cancer represented 23% of all new cancer cases 
between 2004 and 2008, and was a leading cause of mortality representing 13% of all 
cancer deaths. The objective of this study was to perform an economic evaluation 
of fulvestrant 500 mg compared with anastrozole and letrozole used as second line 
endocrine therapies in the treatment of advanced breast cancer in post-menopausal 
women in Norway. Methods: The economic analysis was conducted by using a 
simulation model estimating progression-free survival, overall survival and associ-
ated costs and utility gains over the expected lifetime of the patients. As there are 
no head-to-head trials comparing fulvestrant 500 mg with aromatase inhibitors, 
the clinical evidence for the comparative effectiveness was obtained from a net-
work meta-analysis. The economic evaluation was conducted from a health care 
perspective, with costs and resource use based on published sources and expert 
assessment. Results: The cost-effectiveness ratio of fulvestrant 500 mg versus 
anastrozole 1 mg was 36,000 EUR per quality-adjusted life year (QALY), with incre-
mental costs of 9,600 EUR and incremental QALYs of 0.27. The cost-effectiveness 
ratio of fulvestrant 500 mg versus letrozole 2.5 mg was 62,000 EUR per QALY, with 
incremental costs of 21,000 EUR and incremental QALYs of 0.34. In the sensitivity 
analysis the results were stable for variations of key parameters, such as the time 
horizon, the hazard ratios for overall survival, the choice of parametric distribution 
for progression-free survival and the discount rate. ConClusions: Given an infor-
mal cost-effectiveness threshold of around 70,000 EUR/QALY in Norway, the results 
of the economic evaluations suggest that fulvestrant 500 mg is a cost-effective 
treatment compared with alternative treatments such as anastrozole and letrozole. 
These findings indicate that fulvestrant 500 mg is a valuable treatment option for 
patients with advanced breast cancer in Norway.
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Cost-EffECtivENEss of thE systEmatiC idENtifiCatioN aNd trEatmENt 
of Comorbid maJor dEPrEssioN for PEoPLE with ChroNiC disEasEs: thE 
ExamPLE of CaNCEr
Walker S.1, Walker J.2, Richardson G.1, Palmer S.1, Wu Q.1, Gilbody S.1, Martin P.3,  
Holm Hansen C.3, Sawnhey A.3, Murray G.3, Sculpher M.J.4, Sharpe M.2
1University of York, York, UK, 2University of Oxford, Oxford, UK, 3University of Edinburgh, 
Edinburgh, UK, 4Centre for Health Economics, York, UK
objeCtives: Comorbid major depression occurs in approximately ten percent of peo-
ple suffering from a chronic medical condition such as cancer. A ‘collaborative care’ 
approach can be used to systematically identify and treat comorbid major depression. 
However, we lack information on cost-effectiveness of overall approach as economic 
evaluations published to date have focused solely on the treatment stage. We there-
fore aimed to use the best available evidence to estimate the cost-effectiveness of the 
whole approach (both systematic identification and systematic treatment) compared 
with usual practice, for patients attending specialist cancer clinics. Methods: A 
cost-effectiveness analysis using a decision analytic model structured to reflect both 
the identification and treatment processes. Evidence was taken from reviews of rel-
evant clinical trials and from observational studies, together with data from a large 
depression screening service. Sensitivity and scenario analyses were undertaken 
to determine the effects of variations in depression incidence rates, time horizons, 
patient characteristics and alternative estimates of treatment effect. Probabilistic 
sensitivity analysis was also undertaken. Results: Systematic depression manage-
ment generated more costs than usual practice, but also more quality adjusted life 
years (QALYs). The incremental cost-effectiveness ratio was £11,765 per QALY and the 
probabilities of systematic depression management being cost-effective at thresholds 
of £20,000 and £30,000 per QALY were 0.998 and 1 respectively. Findings were robust to 
tests of variation in key model parameters. ConClusions: A combined approach to 
the systematic identification and treatment of comorbid major depression in cancer 
patients is likely to be cost-effective at widely accepted threshold values. Systematic 
depression management may be a better way of generating QALYs for cancer patients 
than some existing medical and surgical treatments. It could potentially be applied 
to other chronic medical conditions.
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objeCtives: PET-based radiotherapy planning for selective lymph node irradiation 
is an example of the current tendency to individualize treatment in cancer. We 
evaluated the cost-effectiveness of individualized radiotherapy planning, compar-
ing PET-CT-based to CT-based radiotherapy treatment planning in non-small cell 
lung cancer. Methods: Our analysis uses a previously developed decision model. 
The model was based on data for 200 NSCLC patients with inoperable stage I-IIIB, 
provided by the Maastro Clinic. Transition rates in the model were estimated by 
multi-state statistical modelling and include the impact of patient and tumour 
features on disease progression. Resource use estimates, costs and utilities were 
obtained from the database of the Maastro Clinic, the literature and Dutch guide-
lines. Primary outcomes were the difference in life years (LY), quality adjusted life 
 VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  A415
PCN131
Cost-EffECtivENEss of bENdamUstiNE-ritUximab iN first-LiNE 
iNdoLENt NhL: a PatiENt-LEvEL simULatioN
Dewilde S.1, Woods B.2, Castaigne J.G.3, Parker C.2, Dunlop W.3
1SHE, Brussels, Belgium, 2Oxford Outcomes, Oxford, UK, 3Mundipharma International Limited, 
Cambridge, UK
objeCtives: To evaluate the cost-effectiveness of bendamustine-rituximab (B-R) 
compared with standard of care as first-line treatment for patients with advanced 
indolent non-Hodgkin’s lymphoma (NHL) in England and Wales. Methods: A 
patient-level simulation was adapted from the model used by the University of 
Sheffield School of Health and Related Research (ScHARR) in a health technology 
appraisal of rituximab for first-line treatment of follicular lymphoma (the most 
common type of indolent NHL). This approach allowed modelling of the complex 
treatment pathways in indolent NHL; specifically, first-line maintenance and sec-
ond-line treatment choice could be modelled as a function of patient age, and prior 
treatment choice and outcome. Data from a Phase 3 randomised, open-label trial 
by the Study group indolent Lymphomas (StiL) in Germany were used to compare 
B-R with CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, rituxi-
mab). The relative efficacy of CHOP-R and CVP-R (cyclophosphamide, vincristine, 
prednisone, rituximab) was estimated as per the original ScHARR approach. The 
analysis was conducted from the perspective of the National Health Service, using 
a lifetime time horizon. One-way sensitivity and scenario analyses were conducted, 
including one using recently published randomised trial data comparing CVP-R with 
CHOP-R. Results: The base-case deterministic incremental cost-effectiveness ratio 
(ICER) was £5,249 per quality adjusted life year (QALY) for B-R vs. CHOP-R, and £8,092 
per QALY for B-R vs. CVP-R. The alternative scenario using direct data comparing 
CVP-R with CHOP-R more than halved the ICER for B-R vs. CVP-R to £3,468. Owing 
to its better toxicity profile, B-R reduced the cost of treating adverse events by over 
£1,000 per patient vs. CHOP-R. None of the one-way sensitivity or scenario analyses 
increased the ICER above £20,000. ConClusions: The ICERs for B-R vs. CHOP-R and 
CVP-R were below the thresholds normally regarded as cost-effective in England 
and Wales (£20,000 – 30,000 per QALY).
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objeCtives: To assess number needed to treat to avoid an episode of FN (NNT) 
and cost-utility in The Netherlands of PP with once-per-cycle pegfilgrastim vs. no 
prophylaxis and vs. PP with daily G-CSF filgrastim (11-days as per label or 6-days 
suboptimal use) for reducing FN incidence in women with primary breast can-
cer receiving high risk chemotherapy for FN (e.g. TAC, a frequently used reference 
regimen in The Netherlands). Methods: A decision-analytic model was con-
structed from health care-payer perspective. Costs were from official list prices 
(April 2013) or literature and included drugs, drug administration and FN-related 
medical costs and hospitalisations. Effectiveness inputs in terms of relative risk 
reduction (RRR) for FN were based on a recent meta-analysis. Survival and utility 
inputs were modeled from available data for breast cancer patients in the US and 
the UK. Outcomes included NNT and incremental cost effectiveness ratio (ICER) as 
cost per quality-adjusted life-year gained (QALY). Univariate sensitivity analyses 
evaluated the robustness of the model. Results: NNT with pegfilgrastim PP was 
lowest at 4.4, with filgrastim 11-days at 5.6 and filgrastim 6-days at 13.4. In terms 
of cost-utility, pegfilgrastim PP was dominant vs. 11-days filgrastim PP and was 
considered cost-effective vs. no prophylaxis (€ 29,896/QALY) and vs. PP with 6-days 
filgrastim (€ 7,615/QALY). In a scenario analysis reducing the prices of daily G-CSFs 
by 40%, pegfilgrastim PP remained cost-effective. The sensitivity analyses revealed 
that most sensitive variables were FN effectiveness (relative risk reductions), incre-
mental survival assumptions and cost of G-CSFs, and overall the model was robust 
to sensitivity analyses. ConClusions: In a Dutch setting, pegfilgrastim PP offers 
a cost-effective approach to PP of FN. In the cost-utility analysis pegfilgrastim PP 
was dominant vs. 11-days filgrastim PP and cost-effective vs. no prophylaxis and 
6-days filgrastim PP.
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objeCtives: Abiraterone acetate improves overall survival of patients with meta-
static castration-resistant prostate cancer (CRCP). The NICE in the UK has recom-
mended abiraterone as a second line treatment for CRCP after docetaxel. Ministry 
of Health, Labour and Welfare (MHLW) has begun to discuss whether or how to use 
cost-effectiveness data for reimbursement or pricing. The purpose of this study is 
to evaluate cost-effectiveness of abiraterone plus prednisolone compared to pred-
nisolone alone in Japan. Methods: Cost-effectiveness analysis was performed 
using a Markov model (TreeAge Pro 2013) based on data from the randomized control 
trial (COU-AA-301 study) and literature review conducted from the public health 
care payer’s perspective. The (1) abiraterone (1,000 mg once daily and orally) plus 
prednisolone (5 mg twice daily and orally) was compared with (2) prednisolone 
alone. The base case was assumed to be a 69 year-old man with metastatic CRPC. 
The model used a time horizon of 10 years. Outcomes were measured in quality-
adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER) was 
calculated. MHLW has yet to approve abiraterone due to the delay in development, 
and drug cost was estimated based on prices in the UK and the US. Both cost and 
outcomes were discounted at a 2% annual rate based on Japanese guidelines for eco-
objeCtives: To summarize the modeling methods used in published 
cost-effectiveness evaluations of first-line treatment for advanced NSCLC 
patients. Methods: To identify relevant studies, a systematic literature search 
was performed in Medline®, EMBASE®, Medline-In-Process and the CRD data-
base from 2000 to 2013. In addition, Technology Appraisals (TA) were identified by 
searching the NICE, SMC and pCODR websites. Studies were included for review 
based on the following pre-defined criteria; 1) description of cost-effectiveness or 
cost-utility analysis; 2) inclusion of a comparison of drug interventions in first-line 
treatment of advanced NSCLC patients; and 3) results were expressed as cost per 
LY or QALY gained. Results: Out of 1009 unique citations, 21 publications and 
18 TA met the inclusion criteria. The identified cost-utility and cost-effectiveness 
analyses were all performed from a payer perspective for a variety of countries in 
Europe, Asia and North America. The economic value of targeted therapies for first-
line and maintenance treatment for advanced NSCLC patients were evaluated for 
different subpopulations according to histology type (non-squamous, squamous). 
The most commonly used modeling approach was the state-transition model 
with health states reflecting stable disease, progression, and death. Transitions 
between these health states were based on either fixed or time varying transition 
probabilities. Cost-effectiveness analyses that were based on a synthesis of clinical 
efficacy evidence primarily relied on the constant hazard ratio assumption. The 
impact of structural modeling assumptions on cost-effectiveness findings was 
frequently not reported. ConClusions: Based on a review of published cost-
effectiveness evaluations, it was concluded that the rational for certain modeling 
choices are frequently not provided. In particular, choices pertaining to methods 
for clinical evidence synthesis and the impact on cost-effectiveness findings need 
to be justified in a more structured way.
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objeCtives: The optimal treatment choice for the about 64,000 men diagnosed 
with prostate cancer each year in Germany still remains unclear. The objectives 
therefore were to estimate and compare costs under day-to-day conditions of car-
ing for men in Germany with newly diagnosed LCLRPC using hormonal therapy 
(HT), active surveillance (AS), radiotherapy (RT), operation (OP), or watchful waiting 
(WW) – HAROW. Methods: The long-term observational multi-centre HAROW 
study combined data collection from urologists (clinical data; utilized outpatient 
medical services, OMS) and from patients (employment status, QoL by EQ-5D, 
numerous health resource use items). Resource use was valued by year 2010 offi-
cial prices in € . Direct costs (DC) were given by hospital treatment, OMS and drugs, 
inpatient rehabilitation, patients’ co-payments. Indirect costs (IC: sick leave, pre-
mature retirement, premature mortality) were estimated by 2010 gross domestic 
product/capita/day. Costs and quality-adjusted life-years (QALYs) were discounted 
by 3% per annum. Strategies without significant differences in QALYs/patient-year 
(PY) were compared by cost-minimization analysis (CMA) using mean costs/PY, 
remaining strategies by cost-utility analysis. Results: From 07/2008 to 03/2013, 
3063 LCLRPC patients (T1a–T2c, N0, M0; 67.3±7.5 years) were included from 257 
urologists: AS n= 452, RT n= 378, HT n= 210, HT+RT n= 80, combination therapy (CT) 
n= 137, OP n= 1647, other therapy (OT) n= 18, WW n= 141. Observation period: aver-
age 1.9 years, maximum 4.6 years. From the societal perspective (DC+IC), HT+RT 
had the lowest cost/PY (€ 1033), followed by AS (€ 1265), RT (€ 1313), WW (€ 1316), 
HT (€ 1522), CT (€ 3209), OT (€ 5705), and OP had highest cost/PY (€ 6656). From the 
perspective of DC, WW showed he lowest cost/PY (€ 894), followed by RT (€ 905), 
HT+RT (€ 987), AS (€ 1014), HT (€ 1169), OT (€ 2176), CT (€ 2204), and OP had highest 
cost/PY (€ 5374). ConClusions: The HAROW study provides meaningful results 
on costs of different LCLRPC treatment strategies under day-to-day conditions of 
care in Germany to support decision making.
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The second generation of contrast-enhanced ultrasound (CEUS) techniques com-
bines the advantages of ultrasound techniques and the additional information 
provided by the contrast agent. objeCtives: To prove that sulphur hexafluoride 
microbubbles contrast agent used for CEUS is as effective in detecting and ana-
lyzing abnormal-looking areas in the liver as currently used imaging techniques 
(contrast-enhanced CT and MRI: CECT and CEMRI), however the costs of CEUS are 
considerably lower. Methods: Cost-minimization analysis was based on litera-
ture review (last 5 years MEDLINE research, evidence level 1++) and on Hungarian 
financing data. National medical protocols were also considered. Results: Average 
cost per patient of CEUS was 64,5 EUR, while costs of currently used techniques 
were 129 EUR. According to the literature 70% of currently used CT and MRI tech-
niques could be replaced by CEUS. Results made it evident that the equally effective 
contrast-enhanced ultrasound technique is more cost-effective than the currently 
used contrast-enhanced CT and MRI techniques. Health technology assessment 
suggested that the change for the new technology would save 64 509 million EUR 
for the National Health Insurance Fund at the end of the third year of application, 
counting with 5000 cases. ConClusions: The widespread use of cost-effective 
CEUS technology is highly recommended as it is an evidently cost-saving technique 
from the insurer’s point of view. Further assessment is recommended to measure 
clinical parameters, burden of radiology and other quality of life parameters of 
patients, possibly by using a control group if this is ethically viable.
